Page 22 - Recent Operational News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nicox Provides First Quarter 2021 Business Update and Financial Highlights NCX 470 Phase 3 trials in glaucoma on track for top-line results in top-line Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a business update and financial highlights for Q1 2021 for Nicox SA and its subsidiaries (the "Nicox Group"), and updated key expected value-inflection milestones. Key Expected Milestones program in glaucoma : Nicox's lead clinical product candidate, NCX 470, is a novel nitric oxide (NO)-donating prostaglandin analog...

Share this article Share this article LEXINGTON, Mass., March 16, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2020. "2020 was a transformative year for Curis, as we made significant progress in our mission to develop the next generation of targeted cancer therapies that meaningfully improve and extend the lives of patients. Despite the difficulties and uncertainty brought about by the ongoing co...

(1) WEST MELBOURNE, FL / ACCESSWIRE / March 3, 2021 / BK Technologies Corporation (NYSE American:BKTI) today announced financial and operating results for the fourth quarter and year ended December 31, 2020. The Company will host a conference call tomorrow, March 4, 2021 at 9:00AM eastern time. Tim Vitou, BK's President, commented, "We had a strong fourth quarter and full year 2020 performance. Revenue grew 10% to $44.1 million for FY 2020. On a quarterly basis, Q4 revenue grew 43% and we generated an operating profit of $0.9 million. Operating margins were 8.4%, a substantial improvement, co...

Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights Initiated two large clinical trials: Denali, the second Phase 3 of NCX 470 in glaucoma, and Mississippi, a Phase 2b of NCX 4251 in blepharitis Phase 3 clinical trial of ZERVIATE in allergic conjunctivitis initiated by partner Ocumension Therapeutics in China U.S. prescriptions for VYZULTA TM by 56% over Q3 2020 Q4 2020 net revenue of €5.8 million, full year 2020 net revenue of €8.9 million and cash of €47.8 million at December 31, 2020 ...